Optimizing epilepsy management and pregnancy outcomes: the role of therapeutic drug monitoring
Epilepsy & Behavior · 2026-11 · 184 · 111192
DOI: 10.1016/j.yebeh.2026.111192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsy & Behavior, 2026-11. Verfasst von Abrar Al-Faraj und 3 weiteren Autor:innen. Beteiligte Einrichtung: Boston Medical Center, Boston University, Chobanian &Avedisian School of Medicine, United States. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Drug Monitoring, Pregnancy Complications. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To provide an overview of pharmacokinetic changes of antiseizure medications (ASMs) during pregnancy and postpartum period and to emphasize the role of therapeutic drug monitoring (TDM) in clinical management. METHOD: This is a structured literature review of electronic medical databases PubMed, Cochrane, Google Scholar, and the clinical trial database (clinicaltrials.gov) from inception to March 2026, examining ASMs pharmacokinetic changes during pregnancy and postpartum period in people with epilepsy and the role of TDM in clinical management. RESULTS: There are significant pregnancy-induced alterations in ASM pharmacokinetics, particularly increased ASM clearance, which have reshaped clinical practices and dispelled the notion that seizure exacerbation during pregnancy is the result of ASM ineffectiveness. Instead, understanding these predictable physiological changes is essential to avoid significant pregnancy-induced decreases in ASM serum concentrations that can result in breakthrough seizures. Additionally, individual factors may contribute to significant variability in ASM clearance alterations, and more research is needed to clarify management of different ASMs during pregnancy. Presently, TDM at regular intervals during gestation is gaining prominence and has become an indispensable tool in epilepsy care during pregnancy. Growing evidence supports the critical role of TDM in maintaining seizure control during pregnancy while minimizing fetal ASM exposure. CONCLUSIONS: TDM is an essential tool in the management of epilepsy during pregnancy-postpartum to optimize ASM therapy for seizure control, particularly for several ASMs that have demonstrated significant pharmacokinetic changes. Further research is needed to establish optimal monitoring protocols and characterize the pharmacokinetic changes in newer ASMs during pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boston Medical Center, Boston University, Chobanian &Avedisian School of Medicine, United States.
- Department of Neurology, University of Vermont Medical Center, Burlington, VT, United States.
- Beth Israel Deaconess Medical Center, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
- Mass General Brigham, Brigham and Women's Hospital, Division of Epilepsy - Department of Neurology, Division of Women's Health, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic ad…
Zitieren
APA
Al-Faraj, A., Obretenova, S., Pang, T. D., & Voinescu, P. E. (2026). Optimizing epilepsy management and pregnancy outcomes: the role of therapeutic drug monitoring. Epilepsy & Behavior, 184, 111192. https://doi.org/10.1016/j.yebeh.2026.111192
Vancouver
Al-Faraj A, Obretenova S, Pang TD, Voinescu PE. Optimizing epilepsy management and pregnancy outcomes: the role of therapeutic drug monitoring. Epilepsy & Behavior. 2026;184:111192. doi:10.1016/j.yebeh.2026.111192
BibTeX
@article{AlFaraj2026,
author = {Al-Faraj, Abrar and Obretenova, Souzana and Pang, Trudy D and Voinescu, P Emanuela},
title = {Optimizing epilepsy management and pregnancy outcomes: the role of therapeutic drug monitoring},
journal = {Epilepsy & Behavior},
year = {2026},
volume = {184},
pages = {111192},
doi = {10.1016/j.yebeh.2026.111192}
}
EUVIMED